Skip to content

US · TRDA · BIOTECHNOLOGY

Entrada Therapeutics, Inc. (TRDA) intrinsic value and stock valuation

$4.35as of 2026-11-21 · Mkt cap 266.7M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Entrada Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values TRDA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from TRDA’s statements →

Entrada Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boston, MA 02210 entradatx.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$25.4M
20192025
Net income
-$-143.75M
20192025
Free cash flow
-$-129.55M
20192025
Total equity
$306.1M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$25.4M$210.8M$129M$0.00$0.00
Operating income-$-156M$47M-$-3.16M-$-97.25M-$-51.13M
Net income-$-143.75M$65.6M-$-6.68M-$-94.62M-$-51.16M
EPSd-$-3.47M$1.68M-$-202.12K-$-3.02M-$-1.64M
Operating cash flow-$-128.51M-$-41.56M$139.8M-$-93.79M-$-50.86M
Capital expenditure-$-1.04M-$-3.16M-$-5.61M-$-2.89M-$-4.58M
Free cash flow-$-129.55M-$-44.72M$134.2M-$-96.67M-$-55.44M
Total assets$377.4M$526.3M$469.2M$252.1M$305.8M
Total debt$50.9M$59.2M$68.2M$25.9M$0.00
Net debt-$-39.46M-$-42M$630K-$-19.22M-$-291.06M
Total equity$306.1M$428.7M$242.4M$212.6M$298.7M
Cash and short-term investments$295.7M$420M$352M$188.7M$291.1M
Income statement
20252024202320222021
Revenue$25.4M$210.8M$129M$0.00$0.00
Cost of revenue$4.1M$0.00$0.00$0.00$0.00
Gross profit$21.3M$210.8M$129M$0.00$0.00
Research and development expenses$142.3M$125.3M$99.9M$66.6M$35.9M
Selling, general and administrative expenses$41.1M$38.5M$32.3M$30.6M$15.2M
Other expenses-$-6M$0.00$0.00$0.00$0.00
Operating expenses$177.3M$163.8M$132.2M$97.3M$51.1M
Cost and expenses$181.4M$163.8M$132.2M$97.3M$51.1M
Interest income$0.00$19.5M$15.2M$2.63M$0.00
Interest expense$0.00$0.00$0.00$2.63M$0.00
Depreciation and amortization$420K$3.77M$2.84M$1.9M$1.12M
Ebitda-$-142.4M$70.3M$14.9M-$-90.09M-$-50.04M
Operating income-$-156M$47M-$-3.16M-$-97.25M-$-51.13M
Total other income/expenses, net$13.2M$19.5M$15.2M$2.63M-$-30K
Income before tax-$-142.83M$66.5M$12.1M-$-94.62M-$-51.16M
Income tax expense$920K$860K$18.7M$0.00$0.00
Net income-$-143.75M$65.6M-$-6.68M-$-94.62M-$-51.16M
Weighted average shares outstanding$41.4M$37.3M$33.1M$31.3M$31.2M
Weighted average diluted shares outstanding$41.4M$39M$33.1M$31.3M$31.2M
Balance sheet
20252024202320222021
Cash and short-term investments$295.7M$420M$352M$188.7M$291.1M
Net receivables$2.58M$3.68M$5.88M$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$306.3M$440M$369.8M$209.9M$298.7M
Property, plant and equipment, net$67.8M$82.1M$92.7M$33M$6.26M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$71.1M$86.3M$99.4M$42.2M$7.13M
Total assets$377.4M$526.3M$469.2M$252.1M$305.8M
Accounts payable$2.29M$4.26M$3.28M$5.99M$710K
Short-term debt$4.14M$7.56M$7.91M$8.41M$0.00
Deferred revenue$340K$13.7M$132.3M$0.00$0.00
Total current liabilities$24.5M$39.5M$158.8M$22M$6.72M
Long-term debt$46.8M$51.7M$60.3M$17.5M$0.00
Deferred revenue, non-current$0.00$6.51M$7.71M$0.00$0.00
Total non-current liabilities$46.8M$58.2M$68M$17.5M$400K
Capital lease obligations$50.9M$59.2M$68.2M$25.9M$0.00
Total liabilities$71.3M$97.6M$226.8M$39.5M$7.12M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-273.09M-$-129.34M-$-194.97M-$-188.28M-$-93.67M
Accumulated other comprehensive income (loss)$650K-$-40K$200K-$-2.06M$0.00
Total equity$306.1M$428.7M$242.4M$212.6M$298.7M
Total investments$205.3M$318.8M$284.4M$143.6M$0.00
Total debt$50.9M$59.2M$68.2M$25.9M$0.00
Net debt-$-39.46M-$-42M$630K-$-19.22M-$-291.06M
Cash flow statement
20252024202320222021
Net income-$-143.75M$65.6M-$-6.68M-$-94.62M-$-51.16M
Depreciation and amortization$4.1M$3.77M$2.84M$1.9M$1.12M
Stock-based compensation$19.6M$17.9M$13.1M$9.89M$2.53M
Change in working capital-$-4.8M-$-118.85M$136.3M-$-11.11M-$-3.42M
Accounts receivable$2.5M$2.2M$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-1.8M$990K-$-2.81M$5.29M-$-710K
Net cash provided by operating activities-$-128.51M-$-41.56M$139.8M-$-93.79M-$-50.86M
Investments in property, plant and equipment-$-1.04M-$-3.16M-$-5.61M-$-2.89M-$-4.58M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$116.8M-$-27.8M-$-138.4M-$-148.65M-$-4.58M
Common stock issued$890K$99.6M$19.4M$480K$190.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$890K$103M$21M$480K$307.5M
Net change in cash-$-10.82M$33.6M$22.5M-$-245.91M$252M
Cash at end of period$94.3M$105.2M$71.6M$45.2M$291.1M
Operating cash flow-$-128.51M-$-41.56M$139.8M-$-93.79M-$-50.86M
Capital expenditure-$-1.04M-$-3.16M-$-5.61M-$-2.89M-$-4.58M
Free cash flow-$-129.55M-$-44.72M$134.2M-$-96.67M-$-55.44M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Entrada Therapeutics, Inc.

        Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.

        CEO
        Dipal Doshi
        Employees
        152
        Beta
        -0.26

        Explore

        Frequently asked questions

        What is the intrinsic value of Entrada Therapeutics, Inc. (TRDA)?

        Entrada Therapeutics, Inc. (TRDA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is TRDA undervalued?

        TRDA trades at a price of $4.35 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.